Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Profiling of Oncology Patients as Part of Clinical Care and Research
Scientific title
Profiling of Oncology Patients as Part of Clinical Care and Research
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gynecologic Cancer 0 0
Condition category
Condition code

Study type
Observational [Patient Registry]
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Utilisation rates of molecular profiling information.
Timepoint [1] 0 0
3 years
Secondary outcome [1] 0 0
Number of patients where the molecular profiling information guided standard treatment or clinical trial enrollment.
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
Clinical trial accrual rates among patients with available molecular profiling data.
Timepoint [2] 0 0
3 years

Key inclusion criteria
1. Age =18 years.

2. Histological diagnosis of gynaecological cancer OR diagnosis of cancer and candidate
for phase I clinical trial

3. ECOG performance status =2

4. Life expectancy of greater than 3 month

5. Ability to understand and the willingness to sign a written informed consent document.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Any contraindication to biopsy

Study design
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0

Funding & Sponsors
Primary sponsor type
University of Auckland, New Zealand

Ethics approval
Ethics application status

Brief summary
The era of precision medicine is an exciting time for clinicians, scientists and patients
alike. The increasing appreciation and identification of specific mutations that drive
cancers, leaves us on the threshold of a new era in which biomarkers will be used to direct
targeted agents to only those patients most likely to respond. The potential medical and
scientific benefits of such a personalised approach to cancer therapy are immense. However, a
number of barriers challenge successful implementation of this approach of which spatial and
temporal heterogeneity are a major concern.

Gynaecological cancers are a major cause of mortality and morbidity internationally. In
Auckland 150 new patients with ovarian, endometrial or cervical cancer are seen by a medical
oncologist each year. In general, when these diseases recur, there are few effective
therapeutic options and prognosis is poor. Better therapeutic targets and treatments are an
unmet need across these tumour types with treatment paradigms still based upon platinum based

PROSPER (Profiling of Oncology Patients as part of Clinical care and Research) will
investigate the evolution of gynaecological cancers over time and in response to treatment to
develop better biomarkers to guide treatment decisions and ultimately improve patient
outcomes. Biopsies at relapse will be collected and profiled with a 580 cancer gene panel.
Circulating tumour DNA will be collected and analysed alongside biopsies as a potential
non-invasive alternative. Linking genomic and clinical data will allow us to learn more to
begin to change our paradigm of care.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Michelle Wilson, MBChb, FRACP
Address 0 0
University of Auckland, New Zealand
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Michelle Wilson, MBChb, FRACP
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see